Tongue Retaining Device (TRD/TSD): What the Evidence Actually Shows

A tongue retaining device (TRD) is a single-piece oral appliance worn during sleep that holds the tongue in a forward position using a small suction bulb positioned just in front of the lips and teeth. The tongue is drawn into the bulb and held there by negative pressure. Unlike most other anti-snoring or anti-apnea mouthpieces, a TRD has no dental anchorage at all: it does not clip, mold, or attach to the teeth or gums in any way. The idea behind holding the tongue forward is straightforward: during sleep, especially on the back, the base of the tongue can fall backward and narrow or block the airway, and a TRD is designed to prevent that by mechanically fixing the tongue's position for the night.

Tongue Retaining Device vs Tongue Stabilizing Device: Same Category, Two Names

“Tongue retaining device” (TRD) and “tongue stabilizing device” (TSD) are two names for the same category of appliance. Both terms appear interchangeably across the clinical literature and on commercial product pages cited throughout this article — a study or a product page using “TSD” is describing the same suction-bulb mechanism as one using “TRD.”

The device most often confused with a TRD is a mandibular advancement device (MAD) — read AirwayLab's companion article on the mandibular advancement device for the full picture on that category. The mechanisms are genuinely different. A MAD is anchored to the teeth and works by pulling the entire lower jaw forward, which indirectly repositions the base of the tongue along with it. A TRD has no dental anchorage whatsoever and acts on the tongue directly, using suction rather than jaw advancement, which is also why it doesn't require sufficient teeth for retention or load the jaw joint the way a MAD can.

The one trial that compared both device types head-to-head in the same patients — a randomized crossover study published in 2009 in the journal Sleep — found that the two approaches produced a broadly similar reduction in apnea-hypopnea index (AHI) from a baseline around 27 events per hour, but they did not perform equally on every measure. Complete or partial treatment response was reported in 68% of patients on the MAD versus 45% on the TSD, and 91% of patients said they preferred the MAD when given a direct choice between the two. (A note on the numbers: this trial's reported post-treatment AHI values were about 11.7 events/hour on the MAD and 13.2 events/hour on the TSD — those are the values after treatment, not the size of the improvement; the actual reductions from baseline were closer to 15 events/hour on the MAD and 14 on the TSD.) Taken together, this single comparative trial suggests a TRD can get patients to a similar AHI as a MAD on average, but with a lower response rate and a clear patient preference for the MAD.

The short answer: there is real trial evidence that a TRD reduces AHI, but the evidence base is smaller than the evidence behind a MAD, and it deserves an honest reading rather than a flattering one.

Genuine randomized controlled trials of a TRD are limited to two: the head-to-head trial against a MAD described above, and a separate 2008 crossover trial published in Sleep and Breathing that compared an active suction device against a sham/control device. In that trial, the respiratory disturbance index fell from about 15.5 to 8.9 events/hour with the active device — roughly a 4.9-events/hour greater reduction than the control produced — and snoring frequency dropped substantially as well; 54% of participants said they would continue using the suction device alone afterward. One disclosure applies to that trial: its first author reports royalties from a commercial TRD (the MPowRx device, commercialized as Good Morning Snore Solution) and a financial interest in a sleep-technology company — the same conflict noted again in the guideline section below. A separate, frequently cited 2017 pooled analysis in the American Journal of Otolaryngologycombined 16 studies covering 242 patients and reported AHI falling from about 33.6 to 15.8 events/hour on average, a roughly 53% reduction, alongside improvements in oxygen saturation and daytime sleepiness scores. That pooled figure needs a caveat before it's quoted anywhere: those 242 “pooled” patients substantially overlap with several of the individual cohorts discussed elsewhere in this article, so it is not 242 independent patients' worth of confirmation; it's closer to a re-aggregation of a smaller set of overlapping studies.

The clearest, trial-supported prerequisite for TRD candidacy is nasal breathing capacity. In a 2009 retrospective follow-up study (published in the Journal of Clinical Sleep Medicine), nasal obstruction was present in 69% of patients who abandoned the device specifically because of discomfort, a statistically significant association (p<0.01). Since a TRD holds the mouth in a position that generally requires nasal breathing to be comfortable, unmanaged nasal congestion or obstruction is a practical barrier to tolerating the device night after night.

Beyond nasal patency, a broader candidate profile is commonly cited in clinical and manufacturer sources: patients who are edentulous or have insufficient/compromised dentition for a dental-anchored device, patients with temporomandibular joint (TMJ) disorders that make jaw-loading devices uncomfortable, and patients who have tried and not tolerated a MAD. This reasoning is mechanistically sound — a TRD needs no teeth for retention and doesn't load the jaw — but it's important to be direct about the evidence status: no controlled trial was located that enrolled patients specifically by these criteria and reported TRD outcomes in that population. Treat this broader profile as plausible clinical reasoning, not as an evidence-based indication in its own right.

Long-term adherence to a TRD is genuinely poor, and it varies enough by device generation and study population that no single number should be quoted as “the” adherence rate. In the 2009 French cohort mentioned above (an older, fixed-bulb device design, followed by retrospective telephone survey), 52% of respondents said they were still using the device at 5 years (mean follow-up). But that figure comes from 33 of 63 patients who actually answered the follow-up call out of 84 originally analyzed, and non-users were significantly less likely to respond (p<0.01), which means 52% is the optimistic end of the real number. In a newer, titratable-device cohort followed prospectively and published in 2024 in the journal Cranio, only 35.9% of patients were still using the device at 12 months, and just 15.4% (6 patients) were still using it at 30 months. That 2024 study's own conclusion of “good long-term subjective effectiveness” is based entirely on those 6 surviving users: it says nothing about the roughly 85% who had already stopped, so any effectiveness claim from that study needs the survivorship caveat attached. Put plainly: somewhere between roughly half and roughly one-sixth of people who start using a TRD are still using it a year or more in, depending on the device generation and how the study measured it — never one flat number.

The same 2009 French follow-up study also documented concrete reasons people quit, rather than vague “discomfort”: foreign-body sensation or general discomfort (49%), pain (31%), excessive salivation (8%), dry mouth (3%), and cosmetic reasons (3%). Sixty percent of eventual quitters stopped within the first six months. Among the patients who kept using the device, 79% reported using it more than four nights per week, 86% used it more than half the night, 30% reported no side effects at all, and 16% noted some dental or periodontal change over time.

Two branded devices come up most often in the commercial TRD/TSD space: aveoTSD and Good Morning Snore Solution (commercialized from the MPowRx device design). Both use the same suction-bulb mechanism described above.

Is a Tongue Retaining Device “FDA Approved” or FDA Cleared?

Cleared, not approved. The U.S. Food and Drug Administration didn't “approve” aveoTSD; it cleared it through the 510(k) pathway, which is a different (and lower) regulatory bar than full approval. aveoTSD holds FDA 510(k) clearance (K231663, cleared September 2023, regulated under 21 CFR 872.5570 as a Class II device, and available over the counter). What that clearance actually covers matters a lot: the FDA's indication for use, quoted verbatim, states aveoTSD “is intended as an aid in the reduction of snoring for adults at least 18 years old.” That clearance is for snoring, not for obstructive sleep apnea — a real gap worth stating plainly, since the device is often discussed and used in an OSA context despite the clearance itself not covering that use.

aveoTSD

Reported retail pricing for aveoTSD is roughly $90–140. That figure comes from consumer comparison sites rather than the manufacturer's own list price, so treat it as an approximate, not authoritative, number.

Good Morning Snore Solution

Good Morning Snore Solution is reported to retail around $99.94, or roughly $65 per unit when sold in a two-pack — again sourced to consumer comparison sites rather than a manufacturer list price, so treat these figures as approximate as well.

Readers researching “something that holds your tongue” or “mouth device for snoring” will run into several genuinely different product and treatment categories that get blurred together online. They are not interchangeable:

• TRD/TSD(this article) — a passive, single-piece appliance with a suction bulb, worn nightly during sleep, with no dental anchorage.
• eXciteOSA— a completely different device category: an active, daytime neuromuscular electrical stimulation device for the tongue, used 20 minutes once a day while awake and never worn during sleep. It was granted FDA De Novo marketing authorization (DEN200018, decision dated February 2021) as a Class II, prescription-only device regulated separately (21 CFR 872.5575), with its indication for use, quoted verbatim, stating it is intended to “reduce snoring and mild obstructive sleep apnea (AHI<15) for patients that are 18 years or older.” It carries specific contraindications, including an AHI of 15 or above, pregnancy, pacemakers or implanted electrodes, braces or intraoral metal, and mouth ulceration, and its mouthpiece is replaced every three months. eXciteOSA is not a TRD, is not worn during sleep, and should never be described as a type of TRD.
• Myofunctional therapy(oropharyngeal exercises) — active, awake muscle-strengthening exercises for the tongue, lips, and soft palate, done repeatedly over weeks, with no device worn at all, let alone during sleep. A 2020 Cochrane systematic review found moderate-certainty evidence of improved sleepiness (ESS) scores versus a sham comparison, and low-certainty evidence (from 2 studies, 82 participants) of AHI improvement versus sham — but performed measurably worse than CPAP: AHI was on average 9.6 events/hour higher with myofunctional therapy alone compared with CPAP alone. Mechanistically, this is the opposite of a TRD: an active daytime exercise program instead of a passive, sleep-worn suction device.
• MAD (covered in AirwayLab's mandibular advancement device article) — a dental-anchored appliance that advances the jaw, discussed in detail above.

The current U.S. clinical practice guideline on oral appliance therapy, published jointly by the American Academy of Sleep Medicine and the American Academy of Dental Sleep Medicine in 2015, states, verbatim, that “there was insufficient evidence to assess the efficacy of TRDs for the treatment of adult patients with OSA.” That sentence reflects the guideline body's formal position on this device category, and it remains the current U.S. standard-of-care document on oral appliance therapy as of September 2026. One disclosure worth noting: one of the guideline's task-force authors reports royalties from a TRD device (MPowRx, commercialized as Good Morning Snore Solution) and a financial interest in a related sleep-technology company; that conflict, if anything, cuts against his own device category being singled out for insufficient-evidence status rather than in its favor, but it's worth stating plainly.